# ClinicalTrials.gov record NCT02351232

> PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02351232-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02351232-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02351232-liraglutide-v1.json
- Content SHA-256: `2825da23128265516ea14422cd142643f029bd9d660ffcc96a96f1f772763096`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02351232 ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

## Sources

<a id="source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc"></a>
- **ClinicalTrials.gov record NCT02351232 · retained source version 2020-02-12:fe99ba38e8cc44e33a06fca36070c9172d4a7d532881288e92e21e1af07dba9e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02351232) (`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02351232." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02351232-liraglutide-v1.json SHA-256: 2825da23128265516ea14422cd142643f029bd9d660ffcc96a96f1f772763096.